Funding for research is a high priority for Hemophilia of Georgia.
Since 2012, Hemophilia of Georgia has funded gene therapy research at two institutions: St. Jude Children's Research Hospital in Memphis, Tennessee and the Aflac Cancer and Blood Disorders Center at Emory University, Atlanta. Our contributions of over $8 million are to develop a cure for hemophilia (factor VIII, factor IX, and factor VII deficiencies).
Since 2003, Hemophilia of Georgia has funded physician researchers to conduct translational research on bleeding disorders and their complications. Each grant is for $75,000 a year, renewable for up to five years, with an additional $7,500 per year for indirect costs. The grant requires an 80% time commitment to bleeding disorder-related research.
Through this program, Hemophilia of Georgia hopes to help create the next generation of hemostasis researchers. This funding will allow a physician who has completed research training to advance to the status of an independent investigator. Our goal is for the achievements of these scientists to improve the lives of people with bleeding disorders.
Applications are accepted year round. Applicants must have an MD degree and have a minimum of three years of research experience. Because the purpose of this grant program is to further the development of beginning researchers, well-established scientists (including recipients of NIH R01 or NSF grants) are not eligible to apply.
Applicants must be U.S. citizens, have permanent resident status (hold an I-551), or be a non-citizen national. Applicants must be sponsored by a non-federal public or private nonprofit institution that conducts health related research within the U.S. and its possessions. A full-time faculty appointment is required throughout the award period.
Questions about the application process can be addressed to Jeff Cornett, Vice President of Research and Public Policy, via phone (770-518-8272) or email email@example.com.
Read about the current and past Research Grantees.
HoG was a catalyst for the creation of the American Thrombosis and Hemostasis Network (ATHN), a nonprofit organization founded to advance and improve the care of individuals affected by bleeding and thrombotic disorders. ATHN’s mission is to provide stewardship of a secure national database, adherent to all privacy guidelines, which will be used to support clinical outcomes analysis, research, advocacy and public health reporting in the hemostasis and thrombosis community.
Hemophilia of Georgia continues to fund projects that utilize the ATHN database. We fund ATHN 5 – “Comparison of Hepatitis C Virus (HCV) Treatment Regimens in Patients with Hemophilia and Other Bleeding Disorders” with the goal of eradicating hepatitis C from the bleeding disorder community. We also regularly fund ATHN DREAM awards. The DREAM Award (Dataset Research Engagement and ATHN Mentorship Award) is a mentored research grant given collaboratively by the Hemostasis and Thrombosis Research Society (HTRS) and ATHN. Designed to enhance the care of patients with bleeding and clotting disorders, the award provides up to $100,000 over 24 months for young investigators at ATHN-affiliated HTCs, who work under the guidance of experienced mentors.
Hemophilia of Georgia has been a long-time funder of the JGP Research Fellowship program of the National Hemophilia Foundation. Not only do we fully fund fellows, but we have endowed the program to ensure that basic research into bleeding disorders continues.
Hemophilia of Georgia provides funding for research by the Infectious Disease/Hemophilia Program at Emory Midtown and the Hemophilia Treatment Centers at Emory/CHOA and Georgia Regents University. Their research includes not only inherited bleeding disorders but also HIV and hepatitis C.
Stay up-to-date on the research programs we fund by subscribing to our newsletter.